

BETAINE SUPPLEMENTATION REDUCES CONGENITAL DEFECTS INDUCED BY PRENATAL ALCOHOL EXPOSURE

Michiko Watanabe, Ph.D.
FASD Research: Results and Relevance
2017

Co-authors/collaborators

Ganga Karunamuni¹, Shi Gu², Yong Qiu Doughman¹, Megan M. Sheehan², Pei Ma², Lindsay M. Peterson², Kersti K. Linask³, Cameron Petersen², Michael W. Jenkins¹, Andrew M. Rollins², Michiko Watanabe¹

Pediatrics¹, Biomedical Engineering²,
Case Western Reserve University,
Cleveland, OH 44106

Pediatrics³, University of South
Florida, St. Petersburg, FL 33701



Disclosure

- ▣ The authors of this research have no financial or other interests which post a conflict of interest.
- ▣ This research was funded by NIH NHLBI and AHA



Fetal Alcohol Syndrome



- ▣ Craniofacial features
- ▣ Neurobehavioral deficits

- ▣ Cardiac defects
 - Conotruncal defects
 - Ventricular septal defects
 - Cardiac valve defects

Goal: To prevent as many prenatal alcohol exposure induced congenital defects as possible

- ▣ Education – uphill battle!
 - 50% of pregnancies are unplanned
 - Some binge drink alcohol while pregnant
- ▣ Prenatal Supplements
 - methyl donors
 - anti-oxidants



Models & Assays

- ▣ Quail eggs

- ▣ Ethanol Exposure

- 40μl of 50% ethanol in saline (BAC=0.179% g/dL)
- Injected at HH stage 4-5




- ▣ Optical Coherence Tomography (OCT)

- Image at HH stage 19 & 34
- Non-destructive, non-invasive
- Axial/Lateral resolution = 8 μm/10 μm
- Doppler OCT capability
- Environmental control

Previous Work: Late Stages

Control


Ethanol



G. Karunamuni, AJP Heart and Circulatory Physiology, 2014

| | Control | Ethanol Exposed |
|----------------------|-----------|-----------------|
| Survival | 82% | 52% ↓ |
| Normal body/head | 14 (100%) | 7 (58%) ↓ |
| Normal heart | 14 (100%) | 5 (42%) ↓ |
| VSD | 0 (0%) | 5 (42%) ↑ |
| Missing great vessel | 0 (0%) | 3 (25%) ↑ |
| Abnormal valves | 0 (0%) | 3 (25%) ↑ |






Preventing PAE induced CHDs by providing methyl donors






Betaine improves survival and reduced head and body wall defects

| | Number of survivors | Survivors with gross morphological defects |
|-------------------------------|----------------------------|---|
| Uninjected (n=47) | 42 (89%) | 0 (0%) |
| Saline (n=35) | 31 (89%) | 0 (0%) |
| Ethanol (n= 48) | 22 (46%) | 11 (50%) |
| 5 uM betaine w/ethanol (n=62) | 45 (73%) | 12 (27%) |

Betaine prevented great artery defects





Betaine prevented valve defects



Betaine prevents ethanol-induced cardiac defects

| | Control | Ethanol | Betaine/ EtOH |
|---|---------------|----------------|---------------|
| # of embryos | 43 | 12 | 36 |
| Normal heart | 42 (98%) | 5 (42%) | 31 (86%) |
| <u>VSDs</u> | <u>0 (0%)</u> | <u>5 (42%)</u> | <u>0 (0%)</u> |
| Missing vessel | 0 (0%) | 3 (25%) | 2 (6%) |
| DORV | 0 (0%) | 1 (8%) | 1 (3%) |
| Misaligned aorta | 0 (0%) | 1 (8%) | 1 (3%) |
| Hypoplastic right ventricle | 0 (0%) | 1 (8%) | 0 (0%) |
| Abnormal rotation of ventricle | 1 (2%) | 1 (8%) | 1 (3%) |
| <u>Abnormal valve morphology</u> | <u>0 (0%)</u> | <u>3 (25%)</u> | <u>0 (0%)</u> |
| Collateral artery | 0 (0%) | 0 (0%) | 1 (3%) |


DNA Methylation



Anti- 5 methyl cytosine

HH Stage 12 transverse sections at the level of the CNCC * $P \leq 0.05$

Folate normalizes early heart structure and function




Valve leaflet volumes were also normalized

Summary

- ▣ The methyl donor betaine
 - improves survival and reduced head and body defects due to ethanol exposure
 - prevents late cardiac valve and great artery defects
 - normalizes DNA methylation in embryo tissues
- ▣ The methyl donor folic acid...
 - Known to reduce congenital defects including CHDs
 - prevents early abnormalities that could lead to CHDs

PROGRESS TOWARDS OUR GOAL



http://dietpill-reviews.co.uk/wp-content/uploads/2013/07/0527-diet-pill_vg-300x1991.jpg

FUTURE STUDIES

- Test other compounds & combinations
 - Other methyl donors
 - Antioxidants (Glutathione, D3T)
- Test efficacy/safety in the mouse model
- Test timing and mode of supplementation/fortification
- Clinical trials

